What Happens July 24? Predicting the PCAC Outcome for All 7 Peptides

The peptide internet has already decided the outcome of the July 23–24 PCAC meeting: all seven peptides sail through, compounding pharmacies start filling prescriptions by September, and the gray market dies. That narrative is wrong on every count.

Here’s our peptide-by-peptide handicap based on the four evaluation criteria the PCAC actually uses: physical/chemical characterization, safety, effectiveness for the nominated use, and compounding history.

Tier 1: Likely Favorable

BPC-157 — Nominated for Ulcerative Colitis

Our prediction: Favorable recommendation (75% confidence).

BPC-157 has the deepest research base of any peptide on the docket. The Sikiric laboratory has published extensively on BPC-157’s cytoprotective mechanisms, particularly its interaction with the nitric-oxide system and angiogenesis pathways relevant to gastrointestinal healing. The nomination for ulcerative colitis is specific, clinically relevant, and supported by a body of preclinical evidence that’s unusually large for a compounding candidate.

The limitation is that the evidence is overwhelmingly preclinical — rat and mouse models, not human trials. The PCAC has historically been more lenient on this point for 503A candidates than for drug approvals, but committee members may push back on the gap between animal data and a UC indication. BPC-157 also has extensive compounding history pre-2023, which strengthens the “historical use” criterion.

Risk factor: The committee could defer rather than reject, requesting additional human safety data before a final recommendation. Even a deferral would be functionally positive — it signals the pathway is open.

→ Full BPC-157 profile with mechanism of action and research summary

KPV — Nominated for Wound Healing and Inflammatory Conditions

Our prediction: Favorable recommendation (70% confidence).

KPV is the dark horse that deserves more attention. It’s a tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) with well-characterized anti-inflammatory properties. The wound-healing nomination is supported by published data on KPV’s ability to suppress NF-κB signaling and reduce inflammatory cytokine production.

The safety profile is clean — as a naturally occurring peptide fragment, it carries less inherent regulatory concern than synthetic novel compounds. The nomination for “inflammatory conditions” is broad, but the wound-healing component is specific enough to anchor it.

Most readers have never heard of KPV, which is exactly why this is a first-mover authority play. If it passes, search demand will spike with almost zero existing content to compete against.

→ Full KPV profile with anti-inflammatory mechanism deep dive

Tier 2: Coin Flip

TB-500 — Nominated for Wound Healing

Our prediction: 50/50 (could go either way).

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration, angiogenesis, and wound healing. The research base is solid but not deep. The nomination for wound healing aligns with the published data on actin-binding and cell-migration promotion.

The concern is that Thymosin Beta-4 research has been tangled up with performance-enhancement associations (it appeared on WADA’s prohibited list), which creates optics problems even though the nominated use is legitimate. Committee members who have previously signaled concerns about “sports doping” associations may weigh that against the clinical evidence.

Semax — Nominated for Cerebral Ischemia, Migraine, and Trigeminal Neuralgia

Our prediction: 50/50 (strong data, political complexity).

Semax has something none of the other six nominees have: actual clinical use as an approved drug — in Russia. It’s been used clinically for cerebral ischemia and cognitive enhancement since the 1990s, with a well-documented safety and efficacy profile from the Russian pharmaceutical system.

The problem is that the Russian provenance cuts both ways. The clinical data exists, which is a significant advantage over peptides with only preclinical evidence. But the FDA has historically been cautious about relying on foreign regulatory approvals, and the current geopolitical climate doesn’t help. The committee will need to weigh legitimate clinical evidence against the lack of FDA-standard trial data.

→ Full Semax profile with cognitive enhancement research review

Tier 3: Likely Deferred or Rejected

MOTS-C — Nominated for Obesity AND Osteoporosis

Our prediction: Likely deferred (35% chance of favorable).

MOTS-C is a mitochondrial-derived peptide with genuinely fascinating biology. The retrograde mitochondria-to-nucleus signaling mechanism is unlike anything else in the peptide space, and the metabolic data from Changhan Lee’s laboratory at USC is compelling at the preclinical level.

The problem is the double nomination. Being evaluated for both obesity and osteoporosis in a single hearing is ambitious when the human metabolic data is still early-stage. The committee may view this as overreach — trying to get two indications through the door when neither individually meets the evidentiary bar. A more conservative nomination focused on a single indication would have had better odds.

→ Full MOTS-C profile with mitochondrial signaling research

Emideltide / DSIP — Nominated for Opioid Withdrawal, Chronic Insomnia, and Narcolepsy

Our prediction: Likely deferred (25% chance of favorable).

Delta sleep-inducing peptide has the most challenging nomination of the seven. The opioid withdrawal indication puts it squarely in the FDA’s highest-scrutiny regulatory lane — any substance touching opioid use disorder gets extraordinary review. The insomnia and narcolepsy nominations add breadth but thin the evidence for each individual use.

The human evidence base for DSIP is thinner than for BPC-157 or KPV, and the sleep-induction mechanism is less well-characterized than the nomination implies. The committee is unlikely to recommend a substance for opioid withdrawal without robust human safety and efficacy data.

Epitalon — Nominated for Healthy Aging

Our prediction: Likely rejected (20% chance of favorable).

Epitalon has the weakest nomination of the seven, and it’s not close. The “healthy aging” indication is extraordinarily vague — the FDA has never added a substance to the 503A Bulks List for “aging” as a clinical use. The Khavinson laboratory’s telomere-elongation claims, while generating excitement in the longevity community, rest on methodological foundations that don’t meet the evidentiary standard the PCAC typically applies.

The committee needs a specific, defined clinical use to evaluate. “Healthy aging” is a wellness concept, not a clinical indication. Epitalon may need to be renominated with a more precise use — perhaps related to specific age-related conditions where the telomere data is most relevant.

→ Full Epitalon profile with telomere research analysis

What This Means for the Gray Market

Regardless of the PCAC outcome, research-grade peptides remain available through established vendors for legitimate research purposes. The PCAC process is about creating a parallel legal pathway through compounding pharmacies, not about shutting down research use.

If you’re currently sourcing peptides for research, nothing changes on July 24. The vendors below provide third-party tested, COA-verified research compounds:

Frequently Asked Questions

Related Articles